Anti-Neutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis

Preface.- 1 Introduction: Nomenclature and Classification.- 2 Epidemiology.- 3  Genetics.- 4 Pathogenesis B lymphocytes   T lymphocytes.- 5 ANCA: methods and clinical significance.- 6 Activity and Damage.- 7 Eosinophilic Granulomatosis with Polyangiitis (EGPA).- 8 Granulomatosis with Polyangiitis (GPA).- 9 Microscopic Polyangiitis (MPA).- 10 Vasculitis /organs involvement.- 11 ENT involvement.- 12 Lung involvement .- 13 Kidney involvement.- 14 Nervous system involvement. 15 Peripheral Nervous System.- 16 Central Nervous System.- 17 Skin involvement.- 18 Miscellaneous organ/system involvement (heart, gastrointestinal, articular....).- 19 Prognosis and outcome.- 20 Therapy.- Subject Index.

Renato Alberto Sinico is a Professor of Nephrology and Director of the Postgraduate School of Nephrology at Università degli Studi di Milano - Bicocca. From 2005 to 2015 he was responsible for the Clinical Immunology Unit at Ospedale San Carlo Borromeo of Milan, where he has worked since 1980. He has been president of Forum Interdisciplinare delle Malattie Autoimmuni (FIRMA) and secretary of Immunopathology Study Group of the Italian Society of Nephrology. With a special interest in kidney failure, glomerulonephritis, vasculitis, lupus, cryoglobulinemia, rare autoimmune diseases, autoantibodies such as ANCA and anti-DNA, Prof. Sinico works with numerous international journals, and is the author of more than 160 scientific publications.




Loïc Guillevin is a specialist in internal medicine, involved for many years in the management and care of patients affected by systemic vasculitides, like eosinophilic granulomatosis with polyangitis syndrome, but also granulomatous polyangitis granulomatosis, classical or hepatitis B virus (HBV)-related polyarteritis nodosa, microscopic polyangiitis or mixed essential cryoglobulinemia. Founder of the French Vasculitis Study Group (FVSG) counting over 600 French physicians and with strong international contacts. More than 20 prospective therapeutic trials have been conducted so far by the FVSG, with subsequent publications in renowned international medical journals, with major practical findings: the most severe forms of the disease, identified as those having specific renal, cardiac, gastrointestinal and/or central nervous system involvement, should receive a combination of corticosteroids and immunosuppressant, mostly monthly cyclophosphamide pulses. Pr Loïc Guillevin and his main collaborators are currently based in the Department of Internal Medicine, Hôpital Cochin, Université Paris 5, Paris, France. In 2003 the FVSG created its web homepage,primarily dedicated to continuing